Better Health, Brighter Future
LOS ANGELES, California, June 11, 2024 – Takeda (TSE:4502/NYSE:TAK), today announced the expansion of its Los Angeles (LA) plasma-derived therapies (PDT) production capacity for its plasma fractionation. This represents one of Takeda’s largest single investments in manufacturing capacity expansion at the LA site which is Takeda’s largest fractionation site in terms of capacity globally. The project demonstrates the commitment to better serve patients, pushing the boundaries of innovation and fostering sustainable growth within the local community. In addition to the 230 million US dollar investment, more than 125 new positions will be created.
This investment reflects Takeda’s values-based approach of putting patients first and delivering on its commitments to patient, people and planet, underpinned by data and digital. It also aligns with Takeda’s capital allocation policy of “Investing in Growth Drivers,” through focused investments in value-creating business opportunities. This expansion will enable Takeda to meet the growing demand for plasma-derived therapies for people with rare, chronic and genetic diseases, such as immunodeficiencies and bleeding disorders. The increased production capacity resulting from the expansion will impact the lives of patients by ensuring a consistent and reliable supply of plasma-derived therapies.
“We are pleased to make this investment at our LA site, demonstrating our commitment to our manufacturing footprint in the U.S.,” said Thomas Wozniewski, global manufacturing & supply officer at Takeda. “The U.S. is playing a critical role in our global manufacturing network and contributing to our supply chain resilience globally. The new facility will provide additional plasma fractionation capacity of up to 2 million litres per year enabling us to produce more plasma-derived therapies for patients in need.”
“Global demand for plasma-derived therapies has increased over the past 20 years, and continues to grow due to increasing diagnosis rates, improvements in standard of care and broader access to treatment across more countries." said Giles Platford, president, plasma derived therapies at Takeda. “The Los Angeles expansion will support us in serving more patients with life-transforming therapies and help them live a better life.”
With a rich history of more than 70 years, the facility will be built to the highest global manufacturing standards, including the latest automation and advanced digital technologies.
At Takeda, sustainability is the foundation of every business decision and is reflected in this project as it will leverage existing equipment and infrastructure. By optimizing the use of existing resources and utility infrastructure, Takeda is maximizing the value of its investments and minimizing unnecessary expenditures, ultimately ensuring that resources are allocated efficiently to benefit patients and the planet.
By repurposing an existing building and site infrastructure it is anticipated that the expansion project will move swiftly and efficiently, significantly reducing the time typically required for planning and permitting new construction. Leveraging existing infrastructure also aligns with Takeda's commitment to environmental sustainability focused on achieving net-zero greenhouse gas emission in its own operations by 2035, reducing fresh water withdrawal and waste to landfill. By repurposing the building and equipment, Takeda will be able to minimize the environmental impact associated with new construction, reducing waste, and promoting responsible resource management.
Being part of the LA community, we recognize our social responsibility and creating over 125 new long-term positions is one way to contribute to the growth of the local economy. The new positions created by the expansion will also provide opportunities for skills development and training, empowering current employees to grow professionally and contribute to Takeda's innovative work in plasma-derived therapies.
As part of Takeda’s ongoing commitment to developing the Los Angeles site, we also recently finished construction of a new teardown facility. The new automated teardown lines will further support capacity expansion and increase yield. The project is part of a program to refine and innovate our manufacturing processes and underlying technologies, while improving safety and quality, and leveraging the most sustainable and effective digital solutions.
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.
Megan Ostrower
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
This press release may contain information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.